CDK4/6 inhibition promotes anti-tumor immunity through the induction of T cell memory
Journal Title
Cancer Discovery
Publication Type
epub ahead of print
Pharmacological inhibitors of cyclin dependent kinases 4 and 6 (CDK4/6) are an approved treatment for hormone receptor-positive breast cancer and are currently under evaluation across hundreds of clinical trials for other cancer types. The clinical success of these inhibitors is largely attributed to well-defined tumor-intrinsic cytostatic mechanisms, while their emerging role as immunomodulatory agents is less understood. Using integrated epigenomic, transcriptomic and proteomic analyses, we demonstrated a novel action of CDK4/6 inhibitors in promoting the phenotypic and functional acquisition of immunological T cell memory. Short-term priming with a CDK4/6 inhibitor promoted long-term endogenous anti-tumor T cell immunity in mice, enhanced the persistence and therapeutic efficacy of chimeric antigen receptor (CAR)-T cells, and induced an RB-dependent T cell phenotype supportive of favorable responses to immune checkpoint blockade in melanoma patients. Together, these mechanistic insights significantly broaden the prospective utility of CDK4/6 inhibitors as clinical tools to boost anti-tumor T cell immunity.
WEHI Research Division(s)
Immunology; Advanced Technology And Biology
PubMed ID
Terms of Use/Rights Notice
Refer to copyright notice on published article.

Creation Date: 2021-05-17 11:04:13
Last Modified: 2021-05-17 11:48:12
An error has occurred. This application may no longer respond until reloaded. Reload 🗙